Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm study of ALXN1210 in complement inhibitor treatment-naïve adults and adolescents with atypical hemolytic uremic syndrome
2016-002027-29Phase 3Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Complete TMA Response. Status: unknown.
02
Drugs
ravulizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2016-002027-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002027-29.